Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have been given an average rating of “Hold” by the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $27.00.

Several equities analysts recently commented on the stock. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Fulgent Genetics in a research report on Monday, July 6th. Finally, Piper Sandler restated a “neutral” rating and set a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th.

Key Fulgent Genetics News

Here are the key news stories impacting Fulgent Genetics this week:

• Positive Sentiment: Second-quarter revenue rose 4.4% year over year to $85.4 million, supported by Fulgent’s laboratory services and therapeutic development businesses. The company also reported approximately $6.9 million in government award payments over the past year, primarily related to genetic testing services for the Veterans Health Administration. Fulgent Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter, with 68 investors adding FLGT shares and 92 reducing holdings. Recent government contracts and portfolio changes may provide longer-term signals but are less important to the immediate earnings reaction. Fulgent Genetics Q2 2026 Earnings
• Negative Sentiment: Fulgent reported a non-GAAP loss of $0.58 per share, versus the $0.46 loss analysts expected, while revenue of $85.4 million missed the $94.0 million consensus estimate. On a GAAP basis, the net loss was $29.5 million, or $1.05 per share, compared with a profit a year earlier. Fulgent Genetics Reports Q2 Loss, Misses Revenue Estimates
• Negative Sentiment: Profitability and cash generation deteriorated: gross profit fell to $25.7 million, operating loss widened to $36.1 million, operating cash flow was negative $23.8 million, and cash and equivalents declined to $26.3 million. Fulgent Genetics Q2 2026 Earnings
• Negative Sentiment: Management lowered fiscal 2026 guidance to revenue of $330 million-$340 million, below the $351.2 million consensus, and EPS of negative $2.35 to negative $2.22, worse than the expected negative $1.82. The weaker outlook reinforces concerns about sustained losses and margin pressure. Fulgent Genetics Q2 2026 Earnings Call Transcript

Insider Activity

In related news, insider Hanlin Gao sold 1,688 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $30,198.32. Following the transaction, the insider directly owned 990,374 shares in the company, valued at $17,717,790.86. The trade was a 0.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jian Xie sold 2,146 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $38,391.94. Following the completion of the transaction, the chief operating officer directly owned 367,605 shares of the company’s stock, valued at approximately $6,576,453.45. This trade represents a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 5,980 shares of company stock valued at $106,360. 36.18% of the stock is owned by corporate insiders.

Institutional Trading of Fulgent Genetics

Institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC boosted its stake in Fulgent Genetics by 69.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after buying an additional 548 shares in the last quarter. Federated Hermes Inc. increased its holdings in Fulgent Genetics by 1.2% in the 4th quarter. Federated Hermes Inc. now owns 47,102 shares of the company’s stock valued at $1,237,000 after buying an additional 552 shares during the period. Rhumbline Advisers raised its stake in shares of Fulgent Genetics by 2.4% in the 2nd quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after buying an additional 785 shares in the last quarter. Swiss National Bank raised its stake in shares of Fulgent Genetics by 3.2% in the 4th quarter. Swiss National Bank now owns 39,200 shares of the company’s stock valued at $1,030,000 after buying an additional 1,200 shares in the last quarter. Finally, Peapod Lane Capital LLC raised its stake in shares of Fulgent Genetics by 0.7% in the 4th quarter. Peapod Lane Capital LLC now owns 165,781 shares of the company’s stock valued at $4,355,000 after buying an additional 1,202 shares in the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Stock Down 18.1%

Shares of FLGT stock opened at $16.55 on Friday. Fulgent Genetics has a 12 month low of $13.46 and a 12 month high of $31.04. The firm has a market cap of $470.04 million, a PE ratio of -5.87 and a beta of 0.89. The stock has a 50 day moving average of $19.31 and a 200-day moving average of $19.25.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.12). The business had revenue of $85.39 million during the quarter, compared to the consensus estimate of $94.00 million. Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.82%. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, equities analysts predict that Fulgent Genetics will post -2.81 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.